VREOF - Vireo Health International, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.6350
-0.0150 (-2.31%)
At close: 3:43PM EDT
Stock chart is not supported by your current browser
Previous Close0.6500
Open0.6500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.6300 - 0.6799
52 Week Range0.2000 - 2.7150
Volume79,871
Avg. Volume129,029
Market Cap64.002M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • CNW Group

    Cannabis Industry Company Investor Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , June 26, 2020 /CNW/ - Virtual Investor Conferences, the ...

  • GlobeNewswire

    Jushi Holdings Inc. to Acquire a Pennsylvania Grower-Processor Permit Holder; Reaffirms 2021 Revenue Guidance

    Signs Definitive Binding Agreement to Purchase the Equity of a Grower-Processor in Pennsylvania; Solidifies Jushi’s Position in One of the Most Attractive Medical Cannabis.

  • Vireo Health Raises $10.5 Million to Increase Sales Volume and Margin
    CNW Group

    Vireo Health Raises $10.5 Million to Increase Sales Volume and Margin

    MINNEAPOLIS , March 10, 2020 /PRNewswire/ -- Vireo Health International, Inc. ("Vireo" or the "Company") (CNSX: VREO; OTCQX: VREOF), the science-focused multi-state cannabis company with active operations in exclusively medical-only markets and licenses in 10 states and the commonwealth of Puerto Rico , today announced it has closed the first tranche of a non-brokered private placement offering (the "Offering") of 13,651,574 units of the Company (the "Units"). The Offering was organized by Executive Chairman Bruce Linton and was authorized at a price per Unit of CAD $0.77 for up to a total amount of U.S. $10,000,000 . "This financing reflects the confidence of the capital markets in the potential growth of sales and margin for Vireo," said Executive Chairman, Bruce Linton .

  • GlobeNewswire

    CB2 Insights Selected by Vireo Health to Support Medical Cannabis Clinical Trial

    CB2 chosen to advance application with the US FDA for study on safety and efficacy of cannabis-based topical treatments by leading multistate operator, Vireo. Project marks the start of the clinical trial process for Vireo’s topical creams, lotions and gels to be used by patients for pain management. Company will develop full protocols and manage Investigational New Drug (IND) application on behalf of Vireo and will work with the FDA towards approvals.